TY - JOUR
T1 - Acylcarnitines
T2 - Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
AU - Dambrova, Maija
AU - Makrecka-Kuka, Marina
AU - Kuka, Janis
AU - Vilskersts, Reinis
AU - Nordberg, Didi
AU - Attwood, Misty M.
AU - Smesny, Stefan
AU - Sen, Zumrut Duygu
AU - Guo, An Chi
AU - Oler, Eponine
AU - Tian, Siyang
AU - Zheng, Jiamin
AU - Wishart, David S.
AU - Liepinsh, Edgars
AU - Schiöth, Helgi B.
N1 - Funding Information:
Address correspondence to: Helgi B. Schioth, Professor in Pharmacology, Head, Section of Functional Pharmacology, Department of Neuroscience, Uppsala University, Box 593, 75124 Uppsala, Sweden. E-mail: [email protected]; Maija Dambrova, Professor in Pharmacy, Head, Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles Str 21, LV1006, Riga, Latvia. E-mail: [email protected] The authors were supported by the European Union’s Horizon 2020 research and innovation program [Grant 857394], Genome Canada, and the Canadian Foundation for Innovation. H.B.S. is supported by the Swedish Research Council, the Swedish Brain Foundation, and the Novo Nordisk Foundation. The authors declare no conflicts of interest. dx.doi.org/10.1124/pharmrev.121.000408.
Publisher Copyright:
© 2022 by The Author(s).
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Acylcarnitines are fatty acid metabolites that play important roles in many cellular energy metabolism pathways. They have historically been used as important diagnostic markers for inborn errors of fatty acid oxidation and are being intensively studied as markers of energy metabolism, deficits in mitochondrial and peroxisomal
β
-oxidation activity, insulin resistance, and physical activity. Acylcarnitines are increasingly being identified as important indicators in metabolic studies of many diseases, including metabolic disorders, cardiovascular diseases, diabetes, depression, neurologic disorders, and certain cancers. The US Food and Drug Administration-approved drug L-carnitine, along with short-chain acylcarnitines (acetylcarnitine and propionylcarnitine), is now widely used as a dietary supplement. In light of their growing importance, we have undertaken an extensive review of acylcarnitines and provided a detailed description of their identity, nomenclature, classification, biochemistry, pathophysiology, supplementary use, potential drug targets, and clinical trials. We also summarize these updates in the Human Metabolome Database, which now includes information on the structures, chemical formulae, chemical/spectral properties, descriptions, and pathways for 1240 acylcarnitines. This work lays a solid foundation for identifying, characterizing, and understanding acylcarnitines in human biosamples. We also discuss the emerging opportunities for using acylcarnitines as biomarkers and as dietary interventions or supplements for many wide-ranging indications. The opportunity to identify new drug targets involved in controlling acylcarnitine levels is also discussed.
Significance Statement
This review provides a comprehensive overview of acylcarnitines, including their nomenclature, structure and biochemistry, and use as disease biomarkers and pharmaceutical agents. We present updated information contained in the Human Metabolome Database website as well as substantial mapping of the known biochemical pathways associated with acylcarnitines, thereby providing a strong foundation for further clarification of their physiological roles.
AB - Acylcarnitines are fatty acid metabolites that play important roles in many cellular energy metabolism pathways. They have historically been used as important diagnostic markers for inborn errors of fatty acid oxidation and are being intensively studied as markers of energy metabolism, deficits in mitochondrial and peroxisomal
β
-oxidation activity, insulin resistance, and physical activity. Acylcarnitines are increasingly being identified as important indicators in metabolic studies of many diseases, including metabolic disorders, cardiovascular diseases, diabetes, depression, neurologic disorders, and certain cancers. The US Food and Drug Administration-approved drug L-carnitine, along with short-chain acylcarnitines (acetylcarnitine and propionylcarnitine), is now widely used as a dietary supplement. In light of their growing importance, we have undertaken an extensive review of acylcarnitines and provided a detailed description of their identity, nomenclature, classification, biochemistry, pathophysiology, supplementary use, potential drug targets, and clinical trials. We also summarize these updates in the Human Metabolome Database, which now includes information on the structures, chemical formulae, chemical/spectral properties, descriptions, and pathways for 1240 acylcarnitines. This work lays a solid foundation for identifying, characterizing, and understanding acylcarnitines in human biosamples. We also discuss the emerging opportunities for using acylcarnitines as biomarkers and as dietary interventions or supplements for many wide-ranging indications. The opportunity to identify new drug targets involved in controlling acylcarnitine levels is also discussed.
Significance Statement
This review provides a comprehensive overview of acylcarnitines, including their nomenclature, structure and biochemistry, and use as disease biomarkers and pharmaceutical agents. We present updated information contained in the Human Metabolome Database website as well as substantial mapping of the known biochemical pathways associated with acylcarnitines, thereby providing a strong foundation for further clarification of their physiological roles.
UR - http://www.scopus.com/inward/record.url?scp=85132300679&partnerID=8YFLogxK
U2 - 10.1124/pharmrev.121.000408
DO - 10.1124/pharmrev.121.000408
M3 - Review article
C2 - 35710135
AN - SCOPUS:85132300679
SN - 0031-6997
VL - 74
SP - 506
EP - 551
JO - Pharmacological Reviews
JF - Pharmacological Reviews
IS - 3
ER -